Sorbitol increases muscle glucose uptake ex vivo and inhibits intestinal glucose absorption ex vivo and in normal and type 2 diabetic rats.
Previous studies have suggested that sorbitol, a known polyol sweetener, possesses glycemic control potentials. However, the effect of sorbitol on intestinal glucose absorption and muscle glucose uptake still remains elusive. The present study investigated the effects of sorbitol on intestinal glucose absorption and muscle glucose uptake as possible anti-hyperglycemic or glycemic control potentials using ex vivo and in vivo experimental models. Sorbitol (2.5% to 20%) inhibited glucose absorption in isolated rat jejuna (IC50= 14.6% ± 4.6%) and increased glucose uptake in isolated rat psoas muscle with (GU50= 3.5% ± 1.6%) or without insulin (GU50= 7.0% ± 0.5%) in a concentration-dependent manner. Furthermore, sorbitol significantly delayed gastric emptying, accelerated digesta transit, inhibited intestinal glucose absorption, and reduced blood glucose increase in both normoglycemic and type 2 diabetic rats after 1 h of coingestion with glucose. Data of this study suggest that sorbitol exhibited anti-hyperglycemic potentials, possibly via increasing muscle glucose uptake ex vivo and reducing intestinal glucose absorption in normal and type 2 diabetic rats. Hence, sorbitol may be further investigated as a possible anti-hyperglycemic sweetener.
Department of Biochemistry, School of Life Sciences, University of KwaZulu-Natal (Westville Campus), Durban 4000, South Africa.|Department of Biochemistry, School of Life Sciences, University of KwaZulu-Natal (Westville Campus), Durban 4000, South Africa.
Chika Ifeanyi
CI
Chukwuma
Department of Biochemistry, School of Life Sciences, University of KwaZulu-Natal (Westville Campus), Durban 4000, South Africa.|Department of Biochemistry, School of Life Sciences, University of KwaZulu-Natal (Westville Campus), Durban 4000, South Africa.
Md Shahidul
MS
Islam
D065567:Absorption, Physiological / Q000187:drug effects; D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000178:diet therapy* / Q000188:drug therapy / Q000378:metabolism; D004040:Dietary Carbohydrates / Q000378:metabolism; D005746:Gastric Emptying / Q000187:drug effects; D005772:Gastrointestinal Transit / Q000187:drug effects; D005947:Glucose / Q000378:metabolism*; D006943:Hyperglycemia / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D066298:In Vitro Techniques; D061266:Insulin, Short-Acting / Q000494:pharmacology; D007408:Intestinal Absorption / Q000187:drug effects; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism; D007583:Jejunum / Q000187:drug effects / Q000378:metabolism; D007700:Kinetics; D008297:Male; D008687:Metformin / Q000494:pharmacology; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism*; D064427:Nutritive Sweeteners / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D011897:Random Allocation; D017207:Rats, Sprague-Dawley; D013012:Sorbitol / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*
D004040:Dietary Carbohydrates; D007004:Hypoglycemic Agents; D061266:Insulin, Short-Acting; D064427:Nutritive Sweeteners; D013012:Sorbitol; D008687:Metformin; D005947:Glucose
absorption intestinale du glucose; captation musculaire du glucose; diabète de type 2; gastric emptying; intestinal glucose absorption; muscle glucose uptake; rats; sorbitol; type 2 diabetes; vidange gastrique